
The Department of Health and Human Services’ Administration for Strategic Preparedness and Response recently awarded over $500 million to prepare for clinical trial three COVID-19 vaccine candidates that target better or longer-lasting immune response; increase central laboratory capacity for sample testing; and investigate better ways to develop monoclonal antibodies and evaluate and administer vaccines.